RECURRENT KIDNEY WILMS TUMOR
Clinical trials for RECURRENT KIDNEY WILMS TUMOR explained in plain language.
Never miss a new study
Get alerted when new RECURRENT KIDNEY WILMS TUMOR trials appear
Sign up with your email to follow new studies for RECURRENT KIDNEY WILMS TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare cancers: targeted drug larotrectinib tested in small trial
Disease control OngoingThis phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…
Matched conditions: RECURRENT KIDNEY WILMS TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: targeted drug shows promise
Disease control TerminatedThis study tests a drug called DS-8201a (trastuzumab deruxtecan) in children, teens, and young adults whose osteosarcoma, Wilms tumor, or desmoplastic small round cell tumor has come back or not responded to treatment. The drug works like a smart bomb, attaching to cancer cells a…
Matched conditions: RECURRENT KIDNEY WILMS TUMOR
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Matched conditions: RECURRENT KIDNEY WILMS TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Precision drug tipifarnib targets rare HRAS cancers in kids
Disease control OngoingThis study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…
Matched conditions: RECURRENT KIDNEY WILMS TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC